This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Miguel Martín Jiménez, Hospital General Universitario Gregorio Marañon
Sponsor:
Collaborators:
UNC Lineberger Comprehensive Cancer Center
Hospital Universitario Ramon y Cajal
Hospital San Carlos, Madrid
Centro Nacional de Investigaciones Oncologicas CARLOS III
Information provided by (Responsible Party):
Miguel Martín Jiménez, Hospital General Universitario Gregorio Marañon
ClinicalTrials.gov Identifier:
NCT01560663
First received: March 20, 2012
Last updated: March 7, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)